NRX Common Stock Total Equity from 2010 to 2025

NRXP Stock  USD 2.03  0.04  1.93%   
NRX Pharmaceuticals Common Stock Total Equity yearly trend continues to be relatively stable with very little volatility. Common Stock Total Equity is likely to drop to 2,298. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2017-09-30
Previous Quarter
70 K
Current Value
80 K
Quarterly Volatility
28.5 M
 
Covid
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 41.8 K, Interest Expense of 218.5 K or Selling General Administrative of 19.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRX Pharmaceuticals Correlation against competitors.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

Latest NRX Pharmaceuticals' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of NRX Pharmaceuticals over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. NRX Pharmaceuticals' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

NRX Common Stock Total Equity Regression Statistics

Arithmetic Mean37,803,886
Geometric Mean1,360,072
Coefficient Of Variation84.08
Mean Deviation30,013,550
Median64,475,238
Standard Deviation31,787,130
Sample Variance1010.4T
Range64.5M
R-Value(0.88)
Mean Square Error247.2T
R-Squared0.77
Slope(5,865,017)
Total Sum of Squares15156.3T

NRX Common Stock Total Equity History

2025 2298.24
2024 2419.2
2020 2688.0
201924.5 M
201864.5 M

About NRX Pharmaceuticals Financial Statements

NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Common Stock Total Equity2.4 K2.3 K

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.